0000000000681880

AUTHOR

Marialuisa Bocchino

showing 4 related works from this author

Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection

2009

CD8 T-cells contribute to control of Mycobacterium tuberculosis infection, but little is known about the quality of the CD8 T-cell response in subjects with latent infection and in patients with active tuberculosis disease. CD8 T-cells recognizing epitopes from 6 different proteins of Mycobacterium tuberculosis were detected by tetramer staining. Intracellular cytokines staining for specific production of IFN-gamma and IL-2 was performed, complemented by phenotyping of memory markers on antigen-specific CD8 T-cells. The ex-vivo frequencies of tetramer-specific CD8 T-cells in tuberculous patients before therapy were lower than in subjects with latent infection, but increased at four months a…

MaleEpitopes T-Lymphocytelcsh:MedicineCD8-Positive T-LymphocytesEpitopeDiagnostic RadiologyInfectious Diseases/Bacterial InfectionsSpectrum Analysis TechniquesCellular typesCytotoxic T celllcsh:ScienceImage Cytometryeducation.field_of_studyMultidisciplinarybiologyRadiology and ImagingImmune cellsInfection ImagingMiddle AgedFlow CytometryActinobacteriaPhenotypeSpectrophotometryCytokinesWhite blood cellsFemaleCytophotometryResearch Articlemedicine.drugInterleukin 2Cell biologyBlood cellsTuberculosisImaging TechniquesImmunologyPopulationT cellsCytotoxic T cellsResearch and Analysis MethodsMycobacterium tuberculosisDiagnostic MedicineImmunology/Immunity to InfectionsHLA-A2 AntigenmedicineHumansTuberculosiseducationMedicine and health sciencesHLA-A AntigensBacteriaFluorimetrylcsh:ROrganismsBiology and Life SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseVirologyRetractionAnimal cellsImmunology/Immune ResponseImmunologyMycobacterium tuberculosis CD8 T cells Tuberculosis Latent Infectionlcsh:QCD8MycobacteriumPLoS ONE
researchProduct

Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection.

2010

Th1 CD4(+) T cells and their derived cytokines are crucial for protection against Mycobacterium tuberculosis. Using multiparametic flow cytometry, we have evaluated the distribution of seven distinct functional states (IFN-gamma/IL-2/TNF-alpha triple expressors, IFN-gamma/IL-2, IFN-gamma/TNF-alpha or TNF-alpha/IL-2 double expressors or IFN-gamma, IL-2 or TNF-alpha single expressors) of CD4(+) T cells in individuals with latent M. tuberculosis infection (LTBI) and active tuberculosis (TB). We found that triple expressors, while detectable in 85-90%TB patients, were only present in 10-15% of LTBI subjects. On the contrary, LTBI subjects had significantly higher (12- to 15-fold) proportions of…

Interleukin 2AdultCD4-Positive T-LymphocytesMaleTuberculosisSettore MED/17 - Malattie InfettiveImmunologyCell SeparationBiologyLymphocyte ActivationFlow cytometryMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineImmune systemBacterial ProteinsCD4(+) T cells Cytokines Mycobacterium tuberculosis infection Tuberculosis disease interferon-gamma immunological memory disease responses protection cytokine immunity bcg vaccination virusmedicineImmunology and AllergyDistribution (pharmacology)HumansCytokineTuberculosis Pulmonary030304 developmental biologyTuberculosis disease.Settore MED/04 - Patologia Generale0303 health sciencesAntigens Bacterialmedicine.diagnostic_testMycobacterium tuberculosis infectionMycobacterium tuberculosisMiddle Agedbiology.organism_classificationmedicine.diseaseFlow CytometryPhenotypeVirologyCD4+ T cellsBacterial Load3. Good healthImmunologyAcute DiseaseChronic DiseaseCytokinesTumor necrosis factor alphaAcyltransferases030215 immunologymedicine.drugEuropean journal of immunology
researchProduct

Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

2015

Inhalation is the preferred route of drug administration in chronic respiratory diseases because it optimises delivery of the active compounds to the targeted site and minimises side effects from systemic distribution. The choice of a device should be made after careful evaluation of the patient's clinical condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inhalation manoeuvre and to generate sufficient inspiratory flow. These patient factors must be aligned with the specific advantages and limitations of each inhaler when making this important choice. Finally, adherence to treatment is not the responsibility of the patient alone, but should …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveSocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Anti-asthmatic AgentMedication AdherencePulmonary DiseasePulmonary Disease Chronic ObstructiveSuspensionsAdministration InhalationmedicineCOPDHumansPharmacology (medical)Anti-Asthmatic AgentsMetered Dose InhalersRespiratory systemParticle SizeIntensive care medicineAsthmaAdherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical); Medicine (all)COPDInhalationbusiness.industryMedicine (all)InhalerNebulizers and VaporizersBiochemistry (medical)Adherence; Asthma; COPD; Inhaler; Administration Inhalation; Anti-Asthmatic Agents; Dry Powder Inhalers; Humans; Medication Adherence; Metered Dose Inhalers; Particle Size; Pulmonary Disease Chronic Obstructive; Solutions; Suspensions; Nebulizers and Vaporizers; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)InhalerDry Powder InhalersAirway obstructionmedicine.diseaseAsthmaSolutionsInhalationAdherenceAdministrationAdherence; Asthma; COPD; InhalerbusinessPulmonary pharmacologytherapeutics
researchProduct

Corrigendum to “Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?” [YPUPT 31C (2015) 63–67]

2015

NA

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryInhalerBiochemistry (medical)MedicinePharmacology (medical)asthmaSettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory systembusinessIntensive care medicineAffect (psychology)Pulmonary Pharmacology & Therapeutics
researchProduct